The development of allergen-specific immunotherapy in the 1950s and 1980s. Part 9
In 1994, the International Rhinitis Management Working Group published the International Report on the Diagnosis and Treatment of Rhinitis. This guide divided AR into seasonal forms caused by external allergens (pollen) and permanent forms caused by household allergens (house dust and animal hair mites). From the point of view of ASIT, their workload depends on the quality of the injected extracts, which prompted the standardization of therapeutic methods and preparations. This manual allowed performing ASIT in carefully selected patients.
A few years later, in 1997, EAACI issued another document on the positions of local, non-injectable allergen routes. It indicated that the use of sublingual ASIT in clinical practice is a justified, effective method and has a favorable safety profile.
At the threshold of the new millennium, WHO published an important document on ASIT positions. Based on the results of 8 double placebo-controlled randomized trials, the WHO working group stated that sublingual ASIT "can be used as an alternative to injectable therapy in adults." This recommendation has contributed to the growth of the use of sublingual ASIT in Europe as an acceptable treatment option.
The growth of clinical acceptance of ASIT has been helped by new knowledge in immunology, which has revolutionized many branches of medicine. Thanks to the use of the latest molecular biochemical and biophysical methods in the 1980s and 1990s, tremendous progress was made in understanding the immune mechanisms that underlie allergic reactions and their immunomodulation. Focusing on IgE and IgG levels in the 1960s and 1970s, scientists began to study and describe the cellular aspects of immune tolerance in general and T-lymphocytes in particular.
In 1986, Timothy R. Mosman and colleagues created the basis for the "Th1/Th2 paradigm." Starting with mouse models, and then using the human immune system model, two subpopulations of CD4+ (T helper cells) were isolated based on differences in the secretion profile and cytokine levels. It has been proven that the Th1 subpopulation produces interferon- (INF-) and interleukin-2 (IL-2) and 12, as well as activates the production of CD8+ T cells, natural killers and macrophages. Physiologically, the end result of Th1 stimulation is usually the occurrence of intracellular pathogens and delayed-onset hypersensitivity. The Th2 subpopulation produces INF, IL-4, IL-5, and IL-10, which activate B cells and stimulate the production of IgE, which subsequently binds to mast cell receptors and causes the latter to degranulate in the presence of an allergen. Les promotions de 1xBet sont parmi les plus intéressantes du marché des paris en ligne. Lors de votre inscription, en saisissant le 1xbet code promo vous débloquez un bonus de bienvenue de 100 % jusqu’à 130 € pour les sports ou un pack casino de 1950 € avec 150 tours gratuits. Cette offre est spécialement conçue pour les nouveaux membres.
A few years later, in 1997, EAACI issued another document on the positions of local, non-injectable allergen routes. It indicated that the use of sublingual ASIT in clinical practice is a justified, effective method and has a favorable safety profile.
At the threshold of the new millennium, WHO published an important document on ASIT positions. Based on the results of 8 double placebo-controlled randomized trials, the WHO working group stated that sublingual ASIT "can be used as an alternative to injectable therapy in adults." This recommendation has contributed to the growth of the use of sublingual ASIT in Europe as an acceptable treatment option.
The growth of clinical acceptance of ASIT has been helped by new knowledge in immunology, which has revolutionized many branches of medicine. Thanks to the use of the latest molecular biochemical and biophysical methods in the 1980s and 1990s, tremendous progress was made in understanding the immune mechanisms that underlie allergic reactions and their immunomodulation. Focusing on IgE and IgG levels in the 1960s and 1970s, scientists began to study and describe the cellular aspects of immune tolerance in general and T-lymphocytes in particular.
In 1986, Timothy R. Mosman and colleagues created the basis for the "Th1/Th2 paradigm." Starting with mouse models, and then using the human immune system model, two subpopulations of CD4+ (T helper cells) were isolated based on differences in the secretion profile and cytokine levels. It has been proven that the Th1 subpopulation produces interferon- (INF-) and interleukin-2 (IL-2) and 12, as well as activates the production of CD8+ T cells, natural killers and macrophages. Physiologically, the end result of Th1 stimulation is usually the occurrence of intracellular pathogens and delayed-onset hypersensitivity. The Th2 subpopulation produces INF, IL-4, IL-5, and IL-10, which activate B cells and stimulate the production of IgE, which subsequently binds to mast cell receptors and causes the latter to degranulate in the presence of an allergen. Les promotions de 1xBet sont parmi les plus intéressantes du marché des paris en ligne. Lors de votre inscription, en saisissant le 1xbet code promo vous débloquez un bonus de bienvenue de 100 % jusqu’à 130 € pour les sports ou un pack casino de 1950 € avec 150 tours gratuits. Cette offre est spécialement conçue pour les nouveaux membres.